Rhythm Pharmaceuticals, Inc.
Rare neuroendocrine-disease biotech focused on precision MC4R agonists for genetically and hypothalamically driven obesity.
Rare neuroendocrine obesity · MC4R agonists · Commercial + Phase 3
Rare neuroendocrine-disease biotech focused on precision MC4R agonists for genetically and hypothalamically driven obesity.
Rare neuroendocrine obesity · MC4R agonists · Commercial + Phase 3